TERIL carbamazepine 200mg tablet bottle

Maa: Australia

Kieli: englanti

Lähde: Department of Health (Therapeutic Goods Administration)

Osta se nyt

Lataa Pakkausseloste (PIL)
24-08-2020
Lataa Valmisteyhteenveto (SPC)
24-08-2020

Aktiivinen ainesosa:

carbamazepine, Quantity: 200 mg

Saatavilla:

MedTAS Pty Ltd

Lääkemuoto:

Tablet, uncoated

Koostumus:

Excipient Ingredients: pregelatinised maize starch; colloidal anhydrous silica; purified talc; magnesium stearate; sodium starch glycollate; microcrystalline cellulose

Antoreitti:

Oral

Kpl paketissa:

30, 60, 200, 90, 1000

Prescription tyyppi:

(S4) Prescription Only Medicine

Käyttöaiheet:

Epilepsy: Partial seizures with complex or simple symptomatology (with or without loss of consciousness), with or without secondary generalisation. Generalised seizures with a tonic-clonic component. Mixed seizure patterns incorporating the above. Teril is suitable for monotherapy and combination therapy. Teril is usually not effective in absence seizures, atonic seizures or myoclonic seizures and should not be used for status epilepticus (see Precautions). Idiopathic trigeminal neuralgia. For the relief of pain in idiopathic trigeminal neuralgia, trigeminal neuralgia due to multiple sclerosis, and idiopathic glossopharyngeal neuralgia. (Carbamazepine is not a simple analgesic and is not intended for trivial facial pain or headache). Mania and bipolar affective disorders. Treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

Tuoteyhteenveto:

Visual Identification: 9 mm white flat bevelled edged tablet marked CB/200 on one side, G on reverse; Container Type: Bottle; Container Material: HDPE; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius

Valtuutuksen tilan:

Registered

Valtuutus päivämäärä:

1991-09-20

Pakkausseloste

                                TERIL
_contains the active ingredient carbamazepine_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Teril.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have benefits and
risks. Your doctor has weighed the
risks of you taking Teril against the
benefits they expect it will have for
you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, TALK TO YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH YOUR
MEDICINE.
You may need to read it again.
WHAT TERIL IS USED FOR
Teril is used to:
•
control epilepsy, a condition
where you have repeated seizures
(fits)
•
treat trigeminal neuralgia, where
there are sudden, repeated attacks
of facial pain
•
control mania, a mental condition
with episodes of overactivity,
elation or irritability
•
prevent bipolar mood disorder
where periods of mania alternate
with periods of depression.
Teril belongs to a group of medicines
called anticonvulsants. These
medicines are thought to work by
controlling brain chemicals which
send signals to nerves so that seizures
do not happen. Teril also regulates
other nerve functions in the body.
Teril may be used alone or in
combination with other medicines to
treat your condition.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY TERIL HAS BEEN
PRESCRIBED FOR YOU.
Your doctor may have prescribed
Teril for another reason.
Teril is available only with a doctor's
prescription.
There is no evidence that Teril is
addictive.
BEFORE YOU TAKE TERIL
_WHEN YOU MUST NOT TAKE IT_
DO NOT TAKE TERIL IF YOU ARE ALLERGIC
TO:
•
any other medicine containing
carbamazepine (e.g., Tegretol)
•
phenytoin (Dilantin) and
oxcarbazepine (Trileptal), which
are other medicines for epilepsy.
•
tricyclic antidepressants,
medicines used to treat
depression
•
any of the ingredients listed at the
end of this leaflet.
Symptoms of an allergic reaction
may include shortness of breath,
wheezing or difficulty breathing;
swelling o
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                TERIL
_Carbamazepine _
PRODUCT INFORMATION
NAME OF THE MEDICINE
Active ingredient
:
Carbamazepine
Chemical name
:
5H-dibenz(b,f)azepine-5-carboxamide
Structural formula
:
Molecular formula
:
C
15
H
12
N
2
O
Molecular weight
:
236.3
CAS Registry no.
:
298-46-4
DESCRIPTION
Carbamazepine is a white or yellowish-white, crystalline powder;
almost odourless; tasteless or with a slightly
bitter taste. It has a melting point of 189

-193

C. Carbamazepine is practically insoluble in water and in ether,
sparingly soluble in ethanol (96%), and soluble in 10 parts of
chloroform.
Each Teril tablet contains 200 mg of carbamazepine and the following
inactive excipients: microcrystalline
cellulose, pregelatinised maize starch, colloidal anhydrous silica,
purified talc, sodium starch glycollate and
magnesium stearate.
PHARMACOLOGY
PHARMACODYNAMICS
Pharmacotherapeutic groups: antiepileptic, neurotropic and
psychotropic agent.
ATC code: N03 AF01
ANTIEPILEPTIC AGENT
Carbamazepine as an antiepileptic agent has been shown to be effective
in the treatment of partial seizures
(simple and complex) with and without secondary generalisation,
generalised tonic-clonic seizures and
combinations of these seizure types.
In some clinical studies carbamazepine, given as monotherapy to
patients with epilepsy, including children and
adolescents, has been reported to exert a mild psychotropic action,
including a beneficial effect on attentiveness
and cognitive performance and on symptoms of anxiety and depression,
as well as a decrease in irritability and
aggressiveness. Other studies have not confirmed these findings.
TERIL – Product Information
2
NEUROTROPIC AGENT
As a neurotropic agent, carbamazepine is clinically effective in
relieving paroxysmal attacks of pain in
idiopathic trigeminal neuralgia.
PSYCHOTROPIC AGENT
As a psychotropic agent, carbamazepine has shown clinical efficacy as
treatment for mania as well as for the
maintenance treatment of bipolar affective disorders, when given
either as monotherapy or in combination with
neuro
                                
                                Lue koko asiakirja